Public Employees Retirement Association of Colorado Cuts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Public Employees Retirement Association of Colorado lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.7% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 45,690 shares of the company’s stock after selling 1,268 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Moderna were worth $5,426,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Hobbs Group Advisors LLC purchased a new stake in shares of Moderna during the fourth quarter worth about $664,000. Illinois Municipal Retirement Fund lifted its stake in Moderna by 22.1% in the first quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock worth $5,519,000 after purchasing an additional 9,360 shares during the last quarter. Swedbank AB purchased a new position in Moderna during the 1st quarter valued at $3,315,000. Wellington Management Group LLP increased its stake in Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after buying an additional 1,614,460 shares during the period. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Moderna during the first quarter valued at approximately $2,693,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Activity

In related news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total value of $1,908,300.00. Following the sale, the director now directly owns 2,284,015 shares of the company’s stock, valued at approximately $290,572,388.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the transaction, the director now owns 2,284,015 shares in the company, valued at approximately $290,572,388.30. The disclosure for this sale can be found here. Insiders sold 93,158 shares of company stock valued at $11,167,312 in the last quarter. Company insiders own 15.70% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $65.69 on Monday. The firm has a market capitalization of $25.18 billion, a P/E ratio of -4.19 and a beta of 1.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The stock has a fifty day moving average price of $90.07 and a two-hundred day moving average price of $110.96. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period in the prior year, the business earned ($3.62) earnings per share. Moderna’s quarterly revenue was down 29.9% on a year-over-year basis. As a group, analysts anticipate that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of analyst reports. Evercore ISI restated an “in-line” rating and set a $120.00 target price on shares of Moderna in a report on Thursday, June 27th. William Blair reissued a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. JPMorgan Chase & Co. lowered shares of Moderna from a “neutral” rating to an “underweight” rating and cut their price objective for the stock from $88.00 to $70.00 in a research note on Friday, September 13th. TD Cowen reduced their price target on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. Finally, Bank of America dropped their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Moderna currently has a consensus rating of “Hold” and an average target price of $100.44.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.